Scope and claims analysis plus US patent landscape for “Method of treating ischemic events during PCI using cangrelor bolus and 4 μg/kg/min infusion” (US Patent 9,427,448)
US 9,427,448 is a method-of-treatment claim set that anchors around a specific cangrelor IV dosing regimen in the percutaneous coronary intervention (PCI) setting, with claim-dependent coverage for ischemic endpoints (including stent thrombosis), timing windows (during vs after PCI), and combination with a P2Y12 inhibitor. The independent claim is tight on dose (30 μg/kg bolus, then 4 μg/kg/min infusion), route (IV), and timing (longer of at least 2 hours or the duration of PCI). A parallel independent claim adds a combination requirement with another P2Y12 inhibitor (clopidogrel/prasugrel/ticagrelor), including a dependent sequence where clopidogrel is administered after cangrelor.
What does US 9,427,448 claim cover for cangrelor dosing during PCI?
Short answer: The patent claims methods that use IV cangrelor in a 30 μg/kg bolus immediately before PCI followed by continuous IV infusion at 4 μg/kg/min for max(2 hours, duration of PCI) to prevent/reduce ischemic events in PCI patients. It also claims a combination method with an added P2Y12 inhibitor, including clopidogrel administered after cangrelor.
Independent claim 1: cangrelor-only IV regimen for PCI ischemic events
Claim 1 requires all elements:
- Patient context: “undergoing percutaneous coronary intervention (PCI)”
- Indication: “treating, reducing the incidence of, or preventing an ischemic event”
- Drug and composition: “pharmaceutical composition comprising cangrelor”
- Administration route: “administered intravenously”
- Dosing and timing:
- 30 μg/kg bolus before the start of PCI
- Then continuous infusion at 4 μg/kg/min
- Infusion duration is the longer of:
- (a) at least two hours, or
- (b) the duration of the PCI
- Clinical safety qualifier (dependent): no significant increase in severe bleeding or need for transfusions (claim 7)
Practical claim construction points for freedom-to-operate:
- “Before the start of PCI” ties the bolus timing to pre-procedure administration, not prehospital or post-procedure.
- “Longer of (a) at least two hours or (b) duration of the PCI” means the infusion duration tracks PCI duration but has a floor at 2 hours. Any regimen that truncates infusion earlier than the longer value risks non-infringement for claim 1.
- “Continuous infusion” can become a design-around target if a competitor uses intermittent dosing or different infusion patterns that avoid “continuous infusion,” though the doctrine will depend on claim interpretation and evidence.
Dependent claims 2 to 8: endpoint, timing, and PCI subtype refinement
- Claim 2: ischemic event occurs “during PCI”
- Claim 3: ischemic event occurs “after PCI”
- Claim 4: ischemic event selected from:
- stent thrombosis
- myocardial infarction
- ischemia-driven revascularization
- mortality
- Claim 5: stent thrombosis
- Claim 6: intraprocedural stent thrombosis
- Claim 7: method where administration is “not accompanied by a significant increase in severe bleeding or the need for transfusions”
- Claim 8: PCI comprises stent implantation
These dependents widen practical infringement scenarios because a provider could treat the patient in a way that prevents or reduces ischemic events during or after PCI, and still land within the claim scope so long as the base dosing regimen is used.
How broad is claim 9, the cangrelor + other P2Y12 inhibitor combination claim?
Short answer: Claim 9 is another method-of-treatment independent claim that requires both IV cangrelor (same dosing regimen) and a second P2Y12 inhibitor given to the patient. It expands coverage into combination protocols where cangrelor is overlapped with clopidogrel/prasugrel/ticagrelor, with a dependent sequence specifying clopidogrel after cangrelor.
Independent claim 9: cangrelor plus P2Y12 inhibitor
Required elements:
- PCI patient
- Method to treat/reduce/prevent an ischemic event
- Administration includes:
- pharmaceutical composition comprising cangrelor
- a P2Y12 inhibitor
- Route and dosing for cangrelor:
- IV bolus: 30 μg/kg before start of PCI
- IV continuous infusion: 4 μg/kg/min after bolus
- Duration: longer of (a) at least two hours or (b) duration of PCI
- The second P2Y12 inhibitor is not limited to any specific dosing timing beyond later dependent claims
Dependent claims 10 to 14: during/after, specific P2Y12 inhibitors, and sequencing
- Claim 10: events during PCI
- Claim 11: events after PCI
- Claim 12: P2Y12 inhibitor is clopidogrel/prasugrel/ticagrelor
- Claim 13: P2Y12 inhibitor is clopidogrel
- Claim 14: clopidogrel is administered after administration of the cangrelor pharmaceutical composition
This last sequencing point is operational. If a competitor administers clopidogrel before the cangrelor bolus, claim 14 would likely not be met, but claim 13 could still be met depending on how “after” is treated as limiting only for the dependent claim. For a design-around, shifting the timing of clopidogrel relative to cangrelor is a straightforward lever, but the base combination requirement in claim 9 still creates exposure if cangrelor’s dosing and infusion timing are replicated.
Where are the main “infringement gates” in US 9,427,448?
Short answer: The most infringement-driving constraints are (i) the exact cangrelor dose and infusion rate, (ii) the bolus timing relative to PCI start, and (iii) the infusion duration formula; combination claim exposure additionally requires a second P2Y12 inhibitor.
Infringement gate 1: exact dose and rate
- Bolus: 30 μg/kg
- Infusion: 4 μg/kg/min
- Both are required under both independent claims (1 and 9)
If an IV regimen uses a materially different infusion rate (even within the same overall exposure window), it is not covered by the literal regimen requirements. If it uses a different bolus but then matches total exposure by infusion, the claim language still requires the “30 μg/kg bolus” element.
Infringement gate 2: bolus timing relative to PCI
- “Before the start of PCI” is a timing limitation. Post-start bolus would avoid that element.
Infringement gate 3: infusion duration = max(2 hours, PCI duration)
- If a regimen stops at 90 minutes even when the PCI lasts >90 minutes, it fails the “longer of” relationship (subject to interpretation and factual record).
- If a regimen extends beyond the longer-of value, the dosing still includes the claimed duration, which could maintain infringement depending on whether “for the longer of …” reads as “at least” vs exactly that duration. Claim drafting often reads as at least; litigation outcomes hinge on construction.
Infringement gate 4: indication is “ischemic event” during or after PCI
- The ischemic event can be MI, ischemia-driven revascularization, mortality, or stent thrombosis (including intraprocedural).
- Clinical trial endpoints are the typical evidentiary basis.
Infringement gate 5: combination element in claim 9
- A second P2Y12 inhibitor must be present under claim 9.
- Dependent claim 14 adds sequencing for clopidogrel.
What patent landscape surrounds US 9,427,448 for cangrelor PCI methods in the US?
Short answer: Based on claim scope, US 9,427,448 sits in a family typically associated with:
- cangrelor IV dosing regimens for PCI (bolus/infusion schedules),
- overlapping antiplatelet strategies (cangrelor with P2Y12 inhibitors), and
- endpoint-driven claims tying dosing to ischemic outcomes and safety.
Because you only provided the claim text (not the publication number, assignee, earliest priority, or the patent’s specification-linked tables), a complete US patent landscape mapping (family members, continuation filings, expiration dates, and Orange Book tie-ins) cannot be generated accurately from the information supplied.
How do claim 1 vs claim 9 differ for competitive freedom-to-operate?
Short answer: Claim 1 covers cangrelor monotherapy in PCI using the specified dosing. Claim 9 covers cangrelor plus any P2Y12 inhibitor, with dependent claims that narrow to clopidogrel and sequence.
Scenario mapping for exposure
- A competitor using IV cangrelor with the same bolus/infusion regimen but giving no P2Y12 inhibitor: exposure risk aligns with claim 1 only.
- A competitor using the same cangrelor dosing but standard P2Y12 therapy: exposure risk aligns with both claim 1 (if other elements fit) and claim 9 (because the method includes another P2Y12 inhibitor).
- A competitor using the same cangrelor dosing but timing clopidogrel before cangrelor: claim 14 avoided, but claim 13 and claim 9 may still apply depending on sequencing facts and how “after” is treated as a dependent limitation.
Design-around levers implied by claim structure
- Change bolus amount or infusion rate away from 30 μg/kg and 4 μg/kg/min
- Change infusion from “continuous” to an alternative non-continuous administration pattern (would require claim-construction support)
- Change bolus timing to after PCI start
- Stop infusion earlier than max(2 hours, PCI duration)
- In combination protocols, shift P2Y12 timing relative to cangrelor to avoid dependent sequencing claims (but not the base combination claim 9)
What types of patents commonly overlap with this regimen claim in US practice?
Short answer: For this kind of dosing/regimen claim, the adjacent US estate typically includes at least these technical patent buckets:
- method-of-treatment claims tying antiplatelet agents and dosing to PCI ischemic endpoints,
- formulation and administration patents (IV preparation, stability, infusion devices),
- additional regimen patents with different infusion durations or ramp/stop rules,
- overlap patents for bridging strategies with P2Y12 inhibitors.
A full, numbered list of specific US patent numbers and expiration dates cannot be produced without the patent’s bibliographic data and family identifiers.
Key Takeaways
- US 9,427,448 is anchored on a specific IV cangrelor PCI dosing regimen: 30 μg/kg bolus before PCI start, then 4 μg/kg/min continuous infusion for max(2 hours, PCI duration).
- Independent claims cover two modalities: cangrelor alone (claim 1) and cangrelor plus a P2Y12 inhibitor (claim 9).
- Dependent claims add meaningful refinements for event timing (during vs after PCI), endpoint type (including intraprocedural stent thrombosis), and combination sequencing (clopidogrel after cangrelor).
- The strongest infringement gates are exact dosing, bolus timing, and infusion duration formula. Secondary exposure gates are whether a second P2Y12 inhibitor is used and, for claim 14, whether clopidogrel is administered after cangrelor.
FAQs
1) Does US 9,427,448 require that the ischemic event actually occur?
No. The claims cover methods that “treat, reduce the incidence of, or prevent” an ischemic event, which typically includes preventing events rather than requiring an event to occur.
2) If infusion lasts longer than “the longer of at least two hours or the duration of PCI,” is it outside the claim?
The claim language sets a minimum tied to that “longer of” relationship. Extending beyond it still satisfies that element unless construed as a strict end point.
3) Can the method infringe if PCI does not include stent implantation?
Claim 8 requires stent implantation only for that dependent claim. The independent claim 1 is broader than claim 8.
4) Can a protocol avoid claim 14 by giving clopidogrel before cangrelor?
Claim 14 is sequencing-specific. Giving clopidogrel before cangrelor would avoid claim 14, but it would not automatically avoid claim 9 because claim 9 does not require that clopidogrel be after.
5) Which single change is most likely to reduce infringement risk: bolus timing or infusion rate?
Changing the infusion rate away from 4 μg/kg/min is more directly targeted by the literal dosing limitations than changing bolus timing alone, because both elements are enumerated as claim requirements.
References
- US Patent 9,427,448 (provided claim text).
